Morgan Stanley’s KaloBios Pharmaceuticals KBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding KBIO
Morgan Stanley's KBIO Position: Q1 2016 in Review
Morgan Stanley sold out of KaloBios Pharmaceuticals (KBIO) in Q1 2016, closing a stake of 47,139 shares — an estimated $472K sold.
Morgan Stanley first reported a position in KBIO in Q2 2013 and held it in 7 quarters. The position peaked at $472K in Q4 2015. 1 fund tracked by Wall St. Rank holds KBIO as of Q1 2016.
- Morgan Stanley reported no remaining KaloBios Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
- Morgan Stanley sold 47,139 KaloBios Pharmaceuticals shares in Q1 2016, an estimated $472K.
- Morgan Stanley first reported a position in KaloBios Pharmaceuticals in Q2 2013 and held it in 7 quarters.
- Morgan Stanley's KaloBios Pharmaceuticals position peaked at $472K in Q4 2015.
- 1 fund tracked by Wall St. Rank held KaloBios Pharmaceuticals as of Q1 2016.
Based on Morgan Stanley's 13F filing for Q1 2016, filed 12 May 2016.